- Home
- BIIB vs CTRA Comparison
BIIB vs CTRA Comparison
Compare BIIB & CTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CTRA
- Stock Information
- Founded
- BIIB 1978
- CTRA 1989
- Country
- BIIB United States
- CTRA United States
- Employees
- BIIB N/A
- CTRA N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CTRA Oil & Gas Production
- Sector
- BIIB Health Care
- CTRA Energy
- Exchange
- BIIB Nasdaq
- CTRA Nasdaq
- Market Cap
- BIIB 19.9B
- CTRA 18.1B
- IPO Year
- BIIB 1991
- CTRA 1990
- Fundamental
- Price
- BIIB $132.03
- CTRA $29.07
- Analyst Decision
- BIIB Buy
- CTRA Strong Buy
- Analyst Count
- BIIB 27
- CTRA 19
- Target Price
- BIIB $220.50
- CTRA $34.17
- AVG Volume (30 Days)
- BIIB 1.7M
- CTRA 6.9M
- Earning Date
- BIIB 04-23-2025
- CTRA 05-01-2025
- Dividend Yield
- BIIB N/A
- CTRA 3.03%
- EPS Growth
- BIIB 40.28
- CTRA N/A
- EPS
- BIIB 11.18
- CTRA 1.50
- Revenue
- BIIB $9,675,900,000.00
- CTRA $5,244,000,000.00
- Revenue This Year
- BIIB N/A
- CTRA $54.37
- Revenue Next Year
- BIIB N/A
- CTRA $6.41
- P/E Ratio
- BIIB $11.81
- CTRA $19.38
- Revenue Growth
- BIIB N/A
- CTRA N/A
- 52 Week Low
- BIIB $128.51
- CTRA $22.30
- 52 Week High
- BIIB $238.00
- CTRA $29.95
- Technical
- Relative Strength Index (RSI)
- BIIB 33.63
- CTRA 59.16
- Support Level
- BIIB $138.65
- CTRA $28.21
- Resistance Level
- BIIB $144.07
- CTRA $29.82
- Average True Range (ATR)
- BIIB 3.56
- CTRA 0.66
- MACD
- BIIB -0.86
- CTRA 0.08
- Stochastic Oscillator
- BIIB 2.79
- CTRA 77.26
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CTRA Coterra Energy Inc.
Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and NGLs. The company's operations are primarily concentrated in three core operating areas; the Permian Basin in west Texas and southeast New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin in the Mid-Continent region in Oklahoma.